All In Biotech

Drug Trial Radar · NCT07473843

Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia

Phase 3 Single-Arm Open-Label Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent Participants (Age 12 to <18 Years) With Homozygous Familial Hypercholesterolemia (SPRUCE)

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Jul 2028

Study completion Aug 2028

Sponsor

Lead sponsor
Arrowhead PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Mar 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of zodasiran subcutaneous (sc) injection in participants 12 to \<18 years of age with genetically or clinically diagnosed homozygous familial hypercholesterolemia (HoFH) and low-density lipoprotein cholesterol (LDL-C) ≥116 milligrams per deciliter (mg/dL) on maximally tolerated lipid-lowering therapy.

Conditions

  • Homozygous Familial Hypercholesterolemia

Interventions

  • ZodasiranDrug

    By sc injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change from Baseline to Month 12 in Fasting LDL-CTime frame: Baseline, Month 12

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Site

    St Louis, Missouri · Recruiting

  • Research Site

    Viborg, Denmark · Recruiting

  • Research Site

    Warsaw, Poland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.